Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Investigation of the potential of leukoreduction filters in the creation of anti-inflammatory compound

Sahar Balagholi a,b,*, Rasul Dabbaghi b, Saeed Mohammadi a,c, Zahra Abbasi Malati a, Mohammad Reza Javan a, Pyman Eshghi n,d

a Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
b Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
c Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
d Pediatric Congenital Hematologic disorders research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

A R T I C L E I N F O

Keywords:
Betamethasone
IL1
IL1Ra
Leukoreduction filters
SARA-CoV-2

A B S T R A C T

Background: Some viruses such as SARS, SARS-CoV-2, and MERS cause an imbalance in immune responses and leads to an acute inflammatory reaction named cytokine storm. In this situation, an anti-inflammatory component can modulate the immune system and decrease mortality. The aim of this study was investigate the potential of leukoreduction filters (LRFs) in creating an anti-inflammatory compound.

Materials and methods: In this experimental study, firstly optimal dose of the anti-inflammatory drug was obtained through LRFs treatment with 0.1 mg, 0.4 mg, and 0.6 mg of Betamethasone. Then inflammatory and anti-inflammatory cytokine in gene and protein level was evaluated. In the next step, LRFs were categorized into treatment 1, treatment 2, control assay, and control groups and treated with the optimal dose of the drug. Finally, the obtained compound was investigated for the concentration of IL1, IL6, and TNF-α as inflammatory and IL4, IL1Ra, and IL10 as anti-inflammatory cytokines.

Results: The results of the current study showed that the concentration of 0.4 mg of Betamethasone lead to a significant increase of anti-inflammatory cytokine in gene and protein levels. The results also showed that the Betamethasone treated groups (treatment1) causes a significant increase in the secretion of anti-inflammatory cytokine compares to the control while inflammatory cytokine remained at the control level.

Conclusion: The results showed that under influence of anti-inflammatory drug treatments the production and secretion of anti-inflammatory cytokines can be induced in LRFs.

1. Introduction

The immune system in the encounter of microorganisms progresses the inflammatory and anti-inflammatory responses as parallel. At the peak of infection, inflammatory responses increase to control infection, and then anti-inflammatory responses are overcome to regulate the inflammatory response [1–4]. Some viruses such as SARS, SARS-CoV-2, and MERS cause an imbalance in immune responses and lead to cytokine storm [5–6] with high mortality in potentiating patients with abnormal inflammatory responses [7–11]. The use of anti-inflammatory drugs leads to complications in the treatment process due to the suppression of inflammatory responses needed to overcome infection. Nowadays immunomodulatory treatment is used to decrease cytokine storm symptoms, in this regard; some studies focus on MSC cell products (cell, supernatant, and microvesicle) [28–29] and some Studies used inflammatory cytokine blockers to cope with cytokine storm in COVID-19 [12–13]. Various mediators and cytokines are involved in preventing this phenomenon [14–16], and the use of an anti-inflammatory cocktail is needed for more acceptable and repetitive results.

Studies show that activation of monocytes following adhesion secret anti-inflammatory cytokines. In this regard, products such as Orthokine, Regenokine, and Autokine have been commercialized the decrease inflammation in osteoarthritis [17–19]. In Leukocyte-reducing filters (LRFs) Monocytes are separated by the adhesion mechanism [20]. Therefore, LRFs potentially create a suitable space for monocyte
activation and can be a cellular source for the preparation of various cytokines and mediators. Also, cells’ direction to the anti-inflammatory phase can be useful for repeatability. Anti-inflammatory drugs such as betamethasone and dexamethasone increase the secretion of anti-inflammatory cytokines by inducing transcription of anti-inflammatory cytokines genes such as IL10, IL4, TGF-β, IL1RA as well as suppressing the expression of inflammatory cytokines genes such as IL1, IL6, TNF-α \cite{21–27}. Since the leukocytes are trapped in the LRFs, Anti-inflammatory drugs can be removed from the filter after treatment without losing the cells and cells can be incubated for more time and secretion pure cytokines.

In this experimental study, we used Betamethasone as an anti-inflammatory drug to treat the adherent/activated monocytes in the LRFs and evaluated the final compound in terms of inflammatory and anti-inflammatory cytokines secretion profile.

2. Material and method

2.1. Filters preparation

41 BioR blood filters (FRESENIUS KABI, Austria) were collected from Tehran Blood Transfusion Center (TBTC, Iran) after leukodepleting 450 ml of whole blood from normal healthy donors. The exterior surfaces of the filters and tubing were wiped with 70% ethanol (Merck, Germany), and the following procedures were performed in a biosafety cabinet (Jal Tajhiz, Iran). Sterile scissors were used to cut the sealed ends of the tubing. For optimal treatment of the leukocytes in LRFs, the remaining RBCs were removed by rinsing the filter in the direction of blood filtration. One bottle of sterile injectable normal saline (NaCl 0.9%) was connected to the filter, and then pouches of normal saline to filter under influence of gravity. The amount of washing varies from 500 ml to 1000 ml in proportion to the number of trapped RBCs and the number of $< 2 \times 10^6$RBC/ul was considered as the cutoff. (Fig. 1A).

2.2. Betamethasone dose optimisation

9 prepared filters were obtained from the previous step selected to determine of optimal dose of Betamethasone. 3 filter was selected for each 0.1, 0.4, 0.6 mg concentrations. 10 ml of normal saline with a total concentration of 0.1, 0.4, and 0.6 mg of betamethasone was injected into the filters for each dose in direction of blood filtration. Fig. 1B. The input and output filter cords were then locked and placed at 37 °C for 2 h. After this time, the filter was washed with 100 ml of normal saline, and the plasma source was injected into the filter and incubated for 6 h. Also, 3 Filters with 30 min incubation without any treatment were considered as baseline control. Mononuclear cells and plasma were extracted from incubated filters with mechanical forces in the opposite direction of blood filtration. Fig. 1C then the final product was evaluated for IL1, IL6, TNFα, IL1Ra, IL4, and IL10 at gene and protein levels.

2.2.1. ELISA assay

The final product from the previous step was centrifuged at 2000 g for 15 min then the levels of inflammatory cytokines (IL-1β, and IL-6, TNFα), and anti-inflammatory cytokines (IL10, IL1Ra, and IL4) in the obtained plasma were measured by ELISA and commercial kits (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. Detection Sensitivity were 1 pg/ml, 0.7 pg/ml, 6.23 pg/ml 3.9 pg/ml 18.3 pg/ml, 10 pg/ml, for IL-1β, and IL-6, TNFα, IL10, IL1Ra, and IL4 respectively. All assays were run in duplicate.

2.2.2. Gene expression assay

2.2.2.1. Leukocyte extraction and Density gradient cell separation. Cell precipitate obtained from the previous step was suspended and added to a density gradient medium (Inno-train, Germany) in a 2:1 vol ratio in a slow manner in order not to mix the layers. The tube was Centrifuged at 800 x g for 20 min with the brake OFF. The mononuclear cells were harvested carefully by inserting the pipette directly through the upper layer. The harvested cells were washed twice with PBS.

2.2.2.2. RNA extraction and Real-Time PCR. For molecular analyses, RNA extraction was initiated with mononuclear cells lysis induced by TRIzol reagent (Life Technologies Corporation; Carlsbad, CA, USA), followed by the addition of chloroform to extract RNA. Isopropanol was then added to precipitate RNA, followed by dissolution in nuclease-free water. The concentration and purity of the isolated RNA were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific; Wilmington, DE, USA), and the integrity of RNA was verified by agarose gel electrophoresis. To perform quantitative real-time polymerase chain reaction (RT-PCR), oligo dT primers and the SuperScript reverse

Fig. 1. Filter preparation and treatment. Direct washing for RBC removal (A), betamethasone injection in direction of blood filtration (B), and plasma and cell extraction in the opposite direction of blood filtration (C). (Red arrow: direction of blood filtration & Blue arrow: direction of filter manipulation).
transcriptase kit (Promega, USA) were used for reverse transcription. An EvaGreen QPCR master mix (Solis BioDyne, Estonia) was used for RT-PCR, with the following PCR parameters: initial denaturation (one cycle at 95 °C for 15 min); denaturation, amplification, and quantification for 40 cycles at 95 °C for 15 s, 56–64 °C for 17 s, and 72 °C for 25 s; melting curve at 65 °C, with the temperature being gradually increased to 95 °C. The mRNA expression was normalized to that of glyceraldehyde 3-phosphate dehydrogenase mRNA, and the changes were calculated according to the standard curve and efficiency (E) for each primer. Primer sequences used for RT-PCR are listed in Table 1.

### 2.3. Preparation of Treatment groups

8 prepared filters obtained from step 1 were selected for each group. For Treatment 1 preparation, 10 ml of optimum dose of Betamethasone was injected into filters and incubated at 37 °C for 2 h. After this time, the filter was washed with 100 ml of normal saline and a plasma source injected into the filter and was incubated for 8 h. For Control assay preparation 10 ml of normal saline was injected into filters and incubated at 37 °C for 2 h. After this time, the filter was washed with 100 ml of normal saline and a plasma source injected into the filter and was incubated for 8 h. Treatment 2 preparations were conducted through injection of 10 ml of normal saline with a plasma source injected into the filter and kept overnight at 25 °C after this time the filter was washed with 100 ml of normal saline to remove the neutrophil debris then 10 ml of optimum dose of Betamethasone was injected to filters and incubated at 37 °C for 2 h. After this time, the filter was washed with 100 ml of normal saline and a plasma source injected into the filter and was incubated for 8 h. Finally, the Control group was created through plasma source injection to the filter and incubated for 30 min. After incubation time for each group, the plasma was extracted from the filter and centrifuge in 2000 g for 15 min then the incubated plasma was evaluated for inflammatory and anti-inflammatory cytokine concentration. Table 2.

### 2.4. Ethical consideration

The project was approved by the Ethics Committee of the High Institute for Research and Education in Transfusion Medicine. (IR.TMI.REC.1399.010).

### 2.5. Statistical analysis

Statistical analyses were carried out with SPSS software [SPSS 22, IBM]. Quantitative Data obtained from RT-PCR and ELISA was analyzed by a nonparametric test (Kruskal Wallis). A p-value of less than 0.05

| Condition                  | Treatment 1 | Control Assay | Treatment 2 | Control |
|----------------------------|-------------|---------------|-------------|---------|
| Betamethasone injection    | ✓           | –             | ✓           | –       |
| Neutrophil removal         | –           | –             | ✓           | –       |
| Incubation time            | 8 h         | 8 h           | 30 min      |         |

### Table 1

**Primer sequences.**

| Sequence definition | Sense | Antisense |
|---------------------|-------|-----------|
| interleukin 1 beta (IL1B) | CCACAGACCTCCAGAGAATG | GTGCACAGCTGATCGTACAGG |
| interleukin 6 (IL6) | AGACAGCCCTACCTCCATGG | TCTGCCAGTGCCTTTTGCTG |
| interleukin 10 (IL10) | TCTCCAGATGGCTCAGGCAGA | TCGAGAAGGGCTTGCAACCA |
| tumor necrosis factor (TNF) | CTTCTTGTCAGCAGCTT | ATGGGTCAGCCTTTGTCATC |
| interleukin 1 receptor antagonist (IL1Ra) | ATGGAGGGAAGATGTGCCTGTC | GTCTGCTTTCTCTGTGCCTC |
| interleukin 4 (IL4) | CGTAAACAGACATCTGGCCTG | GAGTGTCTCTTCACTGGTCC |

### Table 2

**Treatment groups.**

| Condition                  | Treatment 1 | Control Assay | Treatment 2 | Control |
|----------------------------|-------------|---------------|-------------|---------|
| Betamethasone injection    | ✓           | –             | ✓           | –       |
| Neutrophil removal         | –           | –             | ✓           | –       |
| Incubation time            | 8 h         | 8 h           | 30 min      |         |

### Table 3

**Gene expression profile.**

| Gene          | Concentration (pg/ml) | P Value |
|---------------|-----------------------|---------|
| IL1           | 2431.50 ± 1604.78     | 0.001   |
| IL6           | 745.00 ± 14.34        | 0.021   |
| IL10          | 1501.67 ± 200.14      | 0.086   |
| IL1Ra         | 1576.67 ± 1490.04     | 0.005   |
| IL4           | 1281.50 ± 207.98      | 0.001   |
| TNF-α         | 206.50 ± 78.93        | 0.016   |
| IL1Ra         | 52 ± 5                |         |
| IL4           | 562.50 ± 217.46       | 0.001   |
| TNF-α         | 497 ± 134.83          | 0.038   |
| IL4           | 8386.00 ± 2380.01     | 0.001   |
| Control       | 1841.83 ± 435.20      | 0.001   |

### Table 4

**Cytokine secretion profile.**

| Gene          | Cytokine concentration (pg/ml) | P Value |
|---------------|-------------------------------|---------|
| IL1           | 199.00 ± 64.13                 | –       |
| IL6           | 64.13 ± 11.82                  | –       |
| IL10          | 7.07 ± 5.88                    | –       |
| IL1Ra         | 7.10 ± 5.85                    | –       |
| IL4           | 8.37 ± 9.53                    | –       |
| Control       | 10.54 ± 5.83                   | –       |
| Control       | 1582.91 ± 815.09               | 0.031   |
| IL10          | 25.26 ± 24.42                  | –       |
| Control       | 57.67 ± 35.02                  | –       |
| Control       | 16.75 ± 20.35                  | –       |
| IL1Ra         | 36.33 ± 16.65                  | –       |
| IL4           | 47.67 ± 17.99                  | –       |
| Control       | 5.22 ± 0.83                    | –       |

*a Compare to Control.
indicates the difference is significant.

3. Result

3.1. Determining the optimal dose of Betamethasone

3.1.1. Molecular result

Molecular result showed that 6 h incubation of filters with 0.1 mg, 0.4 mg, and 0.6 mg of Betamethasone causes a significant increase in IL1 gene expression at a concentration of 0.1 mg (P = 0.001) and a significant decrease at a concentration of 0.4 mg (P = 0.021) compared to control. Also, the expression of TNF-α and IL6 genes did not show a significant difference compared to the control. In addition, IL1Ra gene expression showed a significant increase compared to control at concentrations of 0.1 mg (P = 0.005) and 0.4 mg (P = 0.001). Also, an increase in IL10 gene expression was observed in all three concentrations, compared to control, at concentrations of 0.1 mg (P = 0.004) and 0.4 mg (P = 0.016). The same increase was observed in IL4 gene, that was significant at concentrations of 0.1 mg (P = 0.038) and 0.4 mg (P = 0.001). (Table 3).

3.1.2. ELISA result

ELISA results showed that IL1Ra and IL4 concentrations were increased compared to control at concentrations of 0.4 mg of Betamethasone which was significant for IL1Ra (P = 0.031) and borderline for IL4 (P = 0.057). Also, this result showed that the concentration of inflammatory factors such as IL1, TNF-α, and IL6 at 0.4 mg of Betamethasone was lower than 0.1 mg concentration. (Table 4).

According to the result of dose determination, the high expression of the IL10 gene was observed, while cytokine level didn’t change, so an increased secretion of this cytokine was predicted by increment incubation time, therefore the treatment time was raised from 6 h to 8 h for treatment groups.

3.2. Cytokine profile in different groups

The results showed anti-inflammatory factor (IL1Ra, IL10, IL4) had significant increase in the treatment 1 (Beta+/Neut+) group compared to control (P Value = 0.008, 0.002 and 0.008 respectively). The results showed that in the control assay (Beta-/Neut+) group a significant increase in the secretion of IL1 and IL1Ra compared to control is visible (P = 0.014, 0.007 respectively), while other anti-inflammatory factors (IL4, IL10) in the Treatment1 compared to the control assay showed a significant and borderline decrease (P = 0.014, 0.068 respectively). On the other hand, the concentration of inflammatory factors in all groups did not show a significant difference compared to the control and remained within the normal range. (Fig. 2).

4. Discussion

Studies have shown that monocytes’ adhesion to plastic and glass surfaces leads to the creation of an anti-inflammatory cocktail named autologous conditioned serum [17–19], but the efficiency of this product is controversial since the elevation of pro-inflammatory cytokine as well was observed [18,34]. The results of the current study showed that leukocytes trapped in LRFs can direct release the anti-inflammatory cytokines under influence of betamethasone treatment as an anti-inflammatory drug.

In this study, dose optimization results indicate that a 0.4 mg concentration of betamethasone at the level of the gene leads to an increase in the expression of genes related to anti-inflammatory cytokines. While, at the protein level, the level of IL10 cytokine didn’t increase. This result showed that more incubation time is needed to increase the protein levels of IL10 cytokine so the incubation time for the next steps was increased from 6 h to 8 h. The following treatment results showed that IL1Ra cytokines in the treatment1 group didn’t significant difference compared to the treatment2 and control assay groups. In this regard, we interpret that the secretion of this cytokine is more affected by the
activation of monocytes due to their baseline condition (adhesion to LRFs fibers and incubation at 37 °C). However, a significant increase in cytokine levels of IL10, and IL4 in treatment1 compared to the control assay indicates the effect of betamethasone on stimulating the secretion of these anti-inflammatory cytokines. In this regard, Vladimir Riabov describes the development of an optimized cytokine cocktail consisting of IL4/IL10/TGFβ1 (M2Ct) that induces a long-term anti-inflammatory phenotype in human primary monocyte-derived macrophages and induces stable M2-like macrophage phenotype with a significantly decreased proinflammatory cytokine [30]. Accordingly, betamethasone probably progresses M2-like macrophage formation through secretion of IL10, and IL4 from LRFs leukocytosis and finally leads to decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine secretion profile. Ping Liu also reveals that macrophages have both pro-inflammatory (M1) and anti-inflammatory (M2) actions and M2 macrophages have four subtypes (M2a, M2b, M2c, and M2d) that stimulating factors for M2a formation is IL10 and IL4 [31].

In addition, the decrease in IL1Ra secretion in treatment2 (neutrophil depleted) compared to treatment1 showed that neutrophils are also involved in IL1 Ra secretion. In this regard, McColl showed the ability of human neutrophils to produce the IL-1 receptor antagonist (IL-1ra), a 17–23-KD protein to respond to GM-CSF and TNF-alfa [32] also Malyak demonstrate that IL-4 enhanced LPS-induced IL-1ra production by peripheral blood neutrophils and inhibited LPS-induced IL-1 beta production [33]. Moreover, the control assay result showed a significant increase in IL1 level compared to control which was according to Maryin Rutgers study that showed IL1 elevate in autologous conditioned serum compared to control [18,34]. This result showed that betamethasone in treatment1 groups prevents the creation of proinflammatory conditions probably through M2a formation from adherent/activated monocytes.

In summary, this study creates modeling for the direction of LRF leukocytosis to produce various cytokines and mediators under certain circumstances. This compound is more cost-effective than methods such as cloning. The main limitation of this study was the lack of an appropriate template for optimal anti-inflammatory compound concentration as a reference. Therefore animal studies are needed to evaluate the efficacy of the final product (cytokine cocktail or immune cells) through control of cytokine storms or septic shock. Also, it is suggested that the effect of other anti-inflammatory drugs such as methylprednisolone or dexamethasone is evaluated. Moreover, this study can be used as a model for the optimization of vaccines or the creation of a convalescent cocktail from the immune person.

CRediT authorship contribution statement

Sahar Balagholi: Formal analysis, Methodology, Writing Original draft, Data Curation preparation, Investigation Rasul Dabbagh: Conceptualization, Methodology, Investigation, Writing - Review & Editing Saeed Mohammadi: Validation, Methodology, Writing Review & Editing Zahra Abbasi malati: Data Curation, Investigation, Writing Review & Editing Mohammad Reza Javan: Investigation, Validation. Pyman Eshghi: Validation, Methodology, Writing Review & Editing.

Acknowledgments

The study was financially and materially supported by the High Institute for Research and Education in Transfusion Medicine.

Conflict of interest

The authors declare that they have no conflict of interest.

References

[1] Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117(4):1162–72.
[2] Nathan C. Points of control in inflammation. Nature 2002;420(6917):846-52.

[3] Ward NS, Caserley B, Ayala A. The compensatory anti-inflammatory response syndrome (CABS) in critically ill patients. Clin Chest Med 2008;29(4):617–25.
[4] Tracy KJ. The inflammatory cayte. Nature 2002;420(6917):851-9.
[5] Noroozi R, Braničík W, Pyrč K, Labaj PP, Pospiech E, Taheri M, Ghafouri-Fard S. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions. Cytokine 2020;133:155143.
[6] Blanco-Melo D,Nilssonnoten AE, Liu WC, Ubi S, Hoogland D, Moller R, Jordan TX, Oishi K, Panis M, Sacha D, Wang TT. Imbalanced host response to SARS-CoV-2 drives the development of COVID-19. Cell 2020;181(5):1036-45.
[7] Maurau-Varius F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes 2020;69(9):1857-63.
[8] Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieeman M, Dyer MD, Teal TH, Proll S, Van Den Brand J, Zarric R. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009;83(14):7062-74.
[9] Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 2020;3(4):e2005619.
[10] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017;127(1):1–4.
[11] Isser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2016;110(2):141–50.
[12] Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X. Effective treatment of severe COVID-19 patients with Tocilizumab. ChinXiv 2020;72.
[13] Pan Luo, Yi Liu, Qin Qiu, Xianlu Liu, Dong Liu, “Jian Li” Tocilizumab treatment in COVID-19: a single center experience, This article is protected by copyright. All rights reserved. (https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25801).
[14] Yamanaka M, Iwama M, Nakajima J, Fukunaka H, Komai H, Chujou S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care 2020;24(1):1–3.
[15] Soy M, Kesen G, Atägülen P, Tufak P, Atägülen I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020;39:2085-94.
[16] Comi P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydla I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19) or SARS-CoV-2: anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34(2):1.
[17] Meijer H, Reinecke J, Becker C, Tholen G, Mehling P. The production of anti-inflammatory cytokines in whole blood by Physico-chemical induction. Inflamm Res 2003;52(10):404–7.
[18] Rutgers M, Saris DB, Helt WJ, Creemers LB. Cytokine profile of autologous conditioned serum for the treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Rheum Ther 2010;12(3):R114.
[19] Mehling P, Evans C, Mehling W. Effectiveness of anti-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskelet Dis 2014;5(1):76–86.
[20] Bruil A, Beugeling T, Feijen J, van Aken WG. The mechanisms of leukocyte removal by filtration. Transfus Med Rev 1995;9(2):145–66.
[21] Kasat K, Patel H, Predeutschka O, Vancurova I, Davidson D. Anti-inflammatory activity of endogenous and exogenous interleukin 10 versus glucocorticoids on macrophage functions of the newly born. J Perinatol 2014;34(5):380–5.
[22] D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccin Immunol 2013;20(3):319–27.
[23] Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and the development of immunomodulatory therapy. Cell Mol Immunol 2016;13(1):1–10.
[24] Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000;9(7):1651–63.
[25] Holbrook TC, Moore JN. Anti-inflammatory and immune support in endotoxemia and septicism. Vet Clin North Am: Equine Pract 1994;10(3):535–47.
[26] Van Der Poll T, Lowry SF. Epinephrine inhibits endotoxin-induced IL-1β production: roles of tumour necrosis factor-α and IL-10. Am J Physiol-Regul Integr Comp Physiol 1997;273(6):R1895–90.
[27] Van der Poll T, Jansen JD, Endert E, Saarwein HP, Van, Deventer SJ. Noradrenaline inhibits lipopolysaccharide-induced tumour necrosis factor and interleukin 6 production in human whole blood. Infect Immun 1994;62(5):2046–50.
[28] Weiss AR, Dahlke MI. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 2019;10:2352.
[29] Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 2020:100019.
[30] Riabov S, Salazar F, Hitte SS, Gudima A, Schmutermaier C, Barthes J, Knopf- Marques H, Klüter H, Ghannamghami AM, Vrana NE, Kryshkowska J. Generation of anti-inflammatory macrophages for implants and regenerative medicine using self-standing release systems with a phenotype-fixing cytokine cocktail formulation. Acta Biomater 2017;53:389–98.
[31] Liu P, Peng J, Han GH, Ding X, Wei S, Gao G, Huang K, Chang F, Wang Y. Role of macrophages in peripheral nerve injury and repair. Neural Regen Res 2020;15(8):1335.
[32] 16-McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/
macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1992;176(2):593-8.

[33] Malyak M, Smith MF, Abel AA, Arend WP. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1β. J Clin Immunol 1994;14 (1):20-30.

[34] Barreto A, Braun TR. A method to induce Interleukin-1 Receptor Antagonist Protein from autologous whole blood. Cytokine 2016;81:137-41.